{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:16:28Z","timestamp":1791918988389,"version":"4.3.4"},"reference-count":28,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca\/MedImmune"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,9,13]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Angiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells. We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2, in combination with tremelimumab (treme), an IgG2 monoclonal antibody blocking cytotoxic T-lymphocyte-associated protein- (CTLA-4), is safe in patients with advanced melanoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a phase I, 3+3 dose escalation trial, patients with metastatic or unresectable melanoma received treme in combination with MEDI3617. The primary objectives of the study were safety and determination of recommended phase II dose (RP2D). The secondary objectives included determination of 6-month and 1-year overall survival and best overall response rate. Immune cell populations and soluble factors were assessed in peripheral blood and metastatic tumors using Fluorescence activated cell sorting (FACS), Luminex, and multiplexed immunofluorescence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifteen patients (median age: 62) were enrolled in the study (3 patients in cohort 1: treme at 10 mg\/kg and MEDI3617 at 200 mg; and 12 patients in cohort 2: treme at 10 mg\/kg and MEDI3617 at 600 mg). The most common all-grade treatment-related adverse events were rash, pruritus, fatigue, and extremity edema. No dose-limiting toxicities were observed. Cohort 2 was determined to be the RP2D. There were no patients with confirmed immune-related complete response or immune-related partial response. Six of 15 patients had immune-related stable disease, resulting in a disease control rate of 0.40 (95% CI 0.16 to 0.68). An increase in frequencies of circulating inducible T-cell costimulator (ICOS)<jats:sup>+<\/jats:sup> and human leukocyte antigen (HLA)-DR<jats:sup>+<\/jats:sup> CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T cells and production of Interleukin-2 and Interleukin-10 was observed post therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tremelimumab in combination with MEDI3617 is safe in patients with advanced melanoma. Angiopoietin-2 inhibition in combination with immune checkpoint inhibition warrants further exploration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02141542\">NCT02141542<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003318","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T11:31:21Z","timestamp":1636716681000},"page":"e003318","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02141542","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03239145","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-943X","authenticated-orcid":false,"given":"Patrick A","family":"Ott","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nazzaro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L","family":"Pfaff","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evisa","family":"Gjini","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen D","family":"Felt","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn O","family":"Wolff","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth I","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Haq","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"McDermott","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Severgnini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J","family":"Rodig","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Stephen Hodi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"2025100313192488000_9.11.e003318.1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0053"},{"key":"2025100313192488000_9.11.e003318.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2639"},{"key":"2025100313192488000_9.11.e003318.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2006.10.004"},{"key":"2025100313192488000_9.11.e003318.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2894"},{"key":"2025100313192488000_9.11.e003318.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.08.002"},{"key":"2025100313192488000_9.11.e003318.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1615"},{"key":"2025100313192488000_9.11.e003318.7","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0206"},{"key":"2025100313192488000_9.11.e003318.8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10561-018-9734-x","article-title":"Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients","volume":"19","author":"Holland","year":"2018","journal-title":"Cell Tissue Bank"},{"key":"2025100313192488000_9.11.e003318.9","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2019.283","article-title":"Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry","volume":"6","author":"Cunningham","year":"2019","journal-title":"J Biol Methods"},{"key":"2025100313192488000_9.11.e003318.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10616-017-0106-3","article-title":"Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells","volume":"70","author":"Patel","year":"2018","journal-title":"Cytotechnology"},{"key":"2025100313192488000_9.11.e003318.11","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2020.325","article-title":"Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells","volume":"7","author":"Manuszak","year":"2020","journal-title":"J Biol Methods"},{"key":"2025100313192488000_9.11.e003318.12","doi-asserted-by":"publisher","DOI":"10.1002\/path.1618"},{"key":"2025100313192488000_9.11.e003318.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.06.059"},{"key":"2025100313192488000_9.11.e003318.14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0012"},{"key":"2025100313192488000_9.11.e003318.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-343293"},{"key":"2025100313192488000_9.11.e003318.16","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12726"},{"key":"2025100313192488000_9.11.e003318.17","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505505"},{"key":"2025100313192488000_9.11.e003318.18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9670"},{"key":"2025100313192488000_9.11.e003318.19","first-page":"3403","article-title":"Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"2025100313192488000_9.11.e003318.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241484","article-title":"High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer","volume":"15","author":"Sopo","year":"2020","journal-title":"PLoS One"},{"key":"2025100313192488000_9.11.e003318.21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0020"},{"key":"2025100313192488000_9.11.e003318.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1138"},{"key":"2025100313192488000_9.11.e003318.23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"2025100313192488000_9.11.e003318.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0569"},{"key":"2025100313192488000_9.11.e003318.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"2025100313192488000_9.11.e003318.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2025100313192488000_9.11.e003318.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"2025100313192488000_9.11.e003318.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:19:34Z","timestamp":1759522774000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,12]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/jitc-2021-003318"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003318","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}